Abstract:The gold standard for treating peripheral nerve injuries that have large nerve gaps where the nerves cannot be directly sutured back together because it creates tension on the nerve, is to incorporate an autologous nerve graft. However, even with the incorporation of a nerve graft, generally patients only regain a small portion of function in limbs affected by the injury. Although, there has been some promising results using growth factors to induce more axon growth through the nerve graft, many of these previous therapies are limited in their ability to release growth factors in a sustained manner and tailor them to a desired time frame. The ideal drug delivery platform would deliver growth factors at therapeutic levels for enough time to grow axons the entire length of the nerve graft. We hypothesized that mineral coated microparticles (MCMs) would bind, stabilize and release biologically active glial cell-derived neurotrophic factor (GDNF) and nerve growth factor (NGF) in a sustained manner. Therefore, the objective of this study was to test the ability of MCMs releasing growth factors at the distal end of a 10 mm sciatic nerve graft, to induce axon growth through the nerve graft and restore hind limb function. After sciatic nerve grafting in Lewis rats, the hind limb function was tested weekly by measuring the angle of the ankle at toe lift-off while walking down a track. Twelve weeks after grafting, the grafts were harvested and myelinated axons were analyzed proximal to the graft, in the center of the graft, and distal to the graft. Under physiological conditions <i>in vitro</i>, the MCMs delivered a burst release of NGF and GDNF for 3 days followed by a sustained release for at least 22 days. <i>In vivo</i>, MCMs releasing NGF and GDNF at the distal end of sciatic nerve grafts resulted in significantly more myelinated axons extending distal to the graft when compared to rats that received nerve grafts without growth factor treatment. The rats with nerve grafts incorporated with MCMs releasing NGF and GDNF also showed significant improvement in hind limb function starting at 7 weeks postoperatively and continuing through 12 weeks postoperatively when compared to rats that received nerve grafts without growth factor treatment. In conclusion, MCMs released biologically active NGF and GDNF in a sustained manner, which significantly enhanced axon growth resulting in a significant improvement of hind limb function in rats. The animal experiments were approved by University of Wisconsin-Madison Animal Care and Use Committee (ACUC, protocol# M5958) on January 3, 2018.

The Physiologic Basis of Molecular Therapeutics for Peripheral Nerve Injury: A Primer

Biomimetic Strategies for Peripheral Nerve Injury Repair: An Exploration of Microarchitecture and Cellularization

Improving peripheral nerve regeneration: from molecular mechanisms to potential therapeutic targets

State-of-the-Art Techniques in Treating Peripheral Nerve Injury

Biohacking Nerve Repair: Novel Biomaterials, Local Drug Delivery, Electrical Stimulation, and Allografts to Aid Surgical Repair

Peripheral nerve injury and myelination: Potential therapeutic strategies

Advances and Future Applications of Augmented Peripheral Nerve Regeneration

Development of Biomaterials for Addressing Upper Extremity Peripheral Nerve Gaps

In Vitro Models for Peripheral Nerve Regeneration

Innovations in Peripheral Nerve Regeneration

Growth factors: Bioactive macromolecular drugs for peripheral nerve injury treatment – Molecular mechanisms and delivery platforms

The Role of Biomaterials in Peripheral Nerve and Spinal Cord Injury: A Review

Stem‐cell–based therapies to enhance peripheral nerve regeneration

Peripheral Nerve Healing: So Near and Yet So Far

Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury

Combining external physical stimuli and nanostructured materials for upregulating pro-regenerative cellular pathways in peripheral nerve repair

Advances in Biomimetic Nerve Guidance Conduits for Peripheral Nerve Regeneration

Neurotrophins in Peripheral Neuropathy: Exploring Pathophysiological Mechanisms and Emerging Therapeutic Opportunities

Functional recovery after peripheral nerve injury via sustained growth factor delivery from mineral-coated microparticles

Platelet-rich plasma, an adjuvant biological therapy to assist peripheral nerve repair

Insights Into the Role and Potential of Schwann Cells for Peripheral Nerve Repair From Studies of Development and Injury